Aruvant Sciences

Will Chou, M.D., CEO
New York, NY

Virtual Presentation
Aruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. The company has a talented team with extensive experience in the development, manufacturing, and commercialization of gene therapy products. Aruvant’s lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is being studied in a Phase I/II clinical trial, the MOMENTUM study, as a one-time potentially curative treatment for SCD. Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy. The company’s second product candidate, ARU-2801, is in development to cure hypophosphatasia, a devastating, ultra-orphan disorder that affects multiple organ systems and leads to high morbidity and mortality when not treated. Data from preclinical studies with ARU-2801 shows durable improvement in disease biomarkers and increased survival.

By using this website you agree to accept our Privacy Policy and Terms & Conditions